Whole body 360 Degree, 3-Dimensional skin imaging to document change in atopic dermatitis severity following treatment with dupilumab

This study will enroll 15 male and female patients, aged 18 years and above, who are diagnosed with moderate to severe chronic AD and who are candidates for systemic therapy or phototherapy. The decision to prescribe Dupilumab will be made by the treating doctor independently. Participation in the study primarily involves consenting to full-body photography and completion of the DLQI questionnaire. Treatment of patients will follow the Australian prescribing label. Dupilumab (300mg/ml) Trade name: Dupixent Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist. It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the type 1 receptor and both IL-4 and IL-13 signaling via the type 2 receptor. By blocking the IL-4R alpha subunit, Dupilumab inhibits IL-4 and IL-13 cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and immunoglobulin E alleviating AP symptoms. This is an open-label, single-centre observational study looking at the photographic resolution of atopic dermatitis in patients receiving Dupilumab per standard regimen. 15 patients with moderate-to-severe chronic AD will be recruited. The decision to prescribe Dupilumab is made by the treating physician, prior to offering participation in this trial. Affected areas will be photographically mapped with whole body 3-D photography using Canfield Vectra WB360. Patients will take part for a maximum of 52 weeks in this study. The initial screening period is up to 4 weeks followed by scheduled visits at Baseline up to Week 52. The study assessments include; Collecting patient demographics (date of birth, gender, ethnicity and child-bearing potential), Medical history, Concomitant treatment, physical examination, vital signs, whole-body photography, Eczema Area Severity Index, and Dermatology Life Quality Index. All participants will be screened prior to enrolment in the study. The Baseline visit will occur no later than 28 days from Screening visit. Visits 3-10 must occur within 3 days from the scheduled dates based on the Baseline visit. Visits 11-14 must occur within 7 days from the scheduled dates based on the Baseline visit. For the end of study visit, a 7-day window applies based on the Baseline visit. The decision to prescribe Dupilumab is made independently by the treating physician based on the patient's clinical needs, prior to any consideration of participation in this trial. Participants in this study will receive Dupilumab treatment irrespective of their involvement in the trial, and their decision to participate, discontinue participation, or discontinue Dupilumab treatment will not impact their access to standard medical care, including Dupilumab. Enrollment in this observational study does not determine whether the participants receive Dupilumab; rather, it allows researchers to observe and collect data on the outcomes of Dupilumab treatment in a real-world setting. Therefore, participants would receive Dupilumab regardless of their involvement in the study, as it is prescribed independently of the study protocol and based solely on their medical requirements.